Immuno-gene Therapy of Melanoma by Tumor Antigen Epitope Modified IFN-gamma

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2005 Feb 24

PMID 15726359

Authors

Xianghui He

Phoebe Luo

Tom C Tsang

Tong Zhang

David T Harris

Affiliations

Soon will be listed here.

Abstract

Cytokine-based vaccines play a major part in tumor immuno-gene therapy. However, down-regulated antigen expression on tumor cells may diminish the immuno-potentiating aspects of cellular vaccines. In this study, we coexpressed a tumor antigen epitope with IFN-gamma in the same gene by replacing the IFN-gamma signal peptide with an antigen epitope-expressing signal peptide. We then investigated the effect of the antigen epitope-incorporated IFN-gamma on the immunotherapy of murine melanoma B16 tumors. Results showed that TRP-2 epitope-expressing IFN-gamma decreased B16 tumorigenicity and enhanced its immunogenicity after gene transfer. Protective immunity against wild type B16 tumors was induced by vaccination with IFN-gamma transiently gene-modified tumor cells. These data suggest that cellular vaccines engineered to express an antigen epitope within an immunostimulatory cytokine could potentiate the immunization effect.

References

Kumar R, Yoneda J, Fidler I, Dong Z . GM-CSF-transduced B16 melanoma cells are highly susceptible to lysis by normal murine macrophages and poorly tumorigenic in immune-compromised mice. J Leukoc Biol. 1999; 65(1):102-8. DOI: 10.1002/jlb.65.1.102. View

Gorelik E, Jay G, Kwiatkowski B, Herberman R . Increased sensitivity to MHC-nonrestricted lysis of BL6 melanoma cells by transfection with class I H-2Kb gene. J Immunol. 1990; 145(5):1621-32. View

Heinzerling L, Feige K, Rieder S, Akens M, Dummer R, Stranzinger G . Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. J Mol Med (Berl). 2001; 78(12):692-702. DOI: 10.1007/s001090000165. View

Roder J . The beige mutation in the mouse. I. A stem cell predetermined impairment in natural killer cell function. J Immunol. 1979; 123(5):2168-73. View

Vanky F, Hising C, Sjowall K, Larsson B, Rodriguez L, Orre L . Immunogenicity and immunosensitivity of ex vivo human carcinomas: interferon gamma and tumour necrosis factor alpha treatment of tumour cells potentiates their interaction with autologous blood lymphocytes. Cancer Immunol Immunother. 1995; 41(4):217-26. PMC: 11037809. DOI: 10.1007/BF01516996. View

Luo P, Tsang T, Takeuchi C, Dekker J, Badowski M, Harris D . High-efficiency cloning system for versatile adaptation of DNA fragments. Biotechniques. 2002; 33(4):738, 740, 742. DOI: 10.2144/02334bm04. View

Garrido F, Ruiz-Cabello F, Cabrera T, Lopez-Botet M, Stern P . Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today. 1997; 18(2):89-95. DOI: 10.1016/s0167-5699(96)10075-x. View

He X, Tsang T, Luo P, Zhang T, Harris D . Enhanced tumor immunogenicity through coupling cytokine expression with antigen presentation. Cancer Gene Ther. 2003; 10(9):669-77. DOI: 10.1038/sj.cgt.7700618. View

Paillard F . Immuno-gene therapy for myeloma using cytokines. Hum Gene Ther. 1998; 9(1):1-2. DOI: 10.1089/hum.1998.9.1-1. View

10.

Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K . Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993; 90(8):3539-43. PMC: 46336. DOI: 10.1073/pnas.90.8.3539. View

11.

van Slooten M, Storm G, Zoephel A, Kupcu Z, Boerman O, Crommelin D . Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines. Pharm Res. 2000; 17(1):42-8. DOI: 10.1023/a:1007514424253. View

12.

Dranoff G . GM-CSF-secreting melanoma vaccines. Oncogene. 2003; 22(20):3188-92. DOI: 10.1038/sj.onc.1206459. View

13.

McEarchern J, Besselsen D, Akporiaye E . Interferon gamma and antisense transforming growth factor beta transgenes synergize to enhance the immunogenicity of a murine mammary carcinoma. Cancer Immunol Immunother. 1999; 48(2-3):63-70. PMC: 11037152. DOI: 10.1007/s002620050549. View

14.

Asada H, Kishida T, Hirai H, Satoh E, Ohashi S, Takeuchi M . Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex. Mol Ther. 2002; 5(5 Pt 1):609-16. DOI: 10.1006/mthe.2002.0587. View

15.

Bohm W, Thoma S, Leithauser F, Moller P, Schirmbeck R, Reimann J . T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. J Immunol. 1998; 161(2):897-908. View

16.

Park S, Kyin T, Bendelac A, Carnaud C . The contribution of NKT cells, NK cells, and other gamma-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors. J Immunol. 2003; 170(3):1197-201. DOI: 10.4049/jimmunol.170.3.1197. View

17.

Xia D, Zheng S, Zhang W, He L, Wang Q, Pan J . Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen. J Mol Med (Berl). 2003; 81(9):585-96. DOI: 10.1007/s00109-003-0472-5. View

18.

Boehm U, Klamp T, Groot M, Howard J . Cellular responses to interferon-gamma. Annu Rev Immunol. 1997; 15:749-95. DOI: 10.1146/annurev.immunol.15.1.749. View

19.

Goodenow R, Vogel J, Linsk R . Histocompatibility antigens on murine tumors. Science. 1985; 230(4727):777-83. DOI: 10.1126/science.2997918. View

20.

Schreurs M, Eggert A, de Boer A, Vissers J, van Hall T, Offringa R . Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res. 2001; 60(24):6995-7001. View